NOVAVAX INC (NVAX) Stock Price, Quote, News and Overview
NASDAQ:NVAX - Nasdaq - US6700024010 - Common Stock - Currency: USD
NVAX Quote, Performance and Key Statistics
6.01
+0.01 (+0.17%)
The current stock price of NVAX is 6.01 USD. In the past month the price decreased by -20.92%. In the past year, price increased by 46.94%.
NVAX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.81 | 301.01B | ||
| AMGN | AMGEN INC | 13.81 | 147.14B | ||
| GILD | GILEAD SCIENCES INC | 22.63 | 130.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1646.62 | 122.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.3 | 61.38B | ||
| ARGX | ARGENX SE - ADR | 320.27 | 36.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.28B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.70B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.47B | ||
| NTRA | NATERA INC | N/A | 19.23B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.60B | ||
| BIIB | BIOGEN INC | 7.07 | 17.05B |
Related stock screener links
About NVAX
Company Profile
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company is headquartered in Gaithersburg, Maryland and currently employs 952 full-time employees. The firm offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. The company has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The firm is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Company Info
NOVAVAX INC
700 Quince Orchard Road
Gaithersburg MARYLAND 20878 US
CEO: Stanley C. Erck
Employees: 1543
Company Website: https://www.novavax.com/?locale=US
Investor Relations: https://ir.novavax.com/
Phone: 12402682000
NOVAVAX INC / NVAX FAQ
What is the stock price of NOVAVAX INC today?
The current stock price of NVAX is 6.01 USD. The price increased by 0.17% in the last trading session.
What is the ticker symbol for NOVAVAX INC stock?
The exchange symbol of NOVAVAX INC is NVAX and it is listed on the Nasdaq exchange.
On which exchange is NVAX stock listed?
NVAX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NOVAVAX INC stock?
13 analysts have analysed NVAX and the average price target is 18.02 USD. This implies a price increase of 199.83% is expected in the next year compared to the current price of 6.01. Check the NOVAVAX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NOVAVAX INC worth?
NOVAVAX INC (NVAX) has a market capitalization of 966.65M USD. This makes NVAX a Small Cap stock.
How many employees does NOVAVAX INC have?
NOVAVAX INC (NVAX) currently has 1543 employees.
What are the support and resistance levels for NOVAVAX INC (NVAX) stock?
NOVAVAX INC (NVAX) has a support level at 5.85 and a resistance level at 6.02. Check the full technical report for a detailed analysis of NVAX support and resistance levels.
Is NOVAVAX INC (NVAX) expected to grow?
The Revenue of NOVAVAX INC (NVAX) is expected to decline by -1.31% in the next year. Check the estimates tab for more information on the NVAX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NOVAVAX INC (NVAX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NVAX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NVAX, evaluating the profitability, health, valuation and growth aspects
- NOVAVAX INC (NVAX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NOVAVAX INC (NVAX) Sales and EPS estimates to see what analysts future expectations are.
- NOVAVAX INC (NVAX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NOVAVAX INC (NVAX) Insider and Institutional Ownership to learn about the owners and their transactions.
- NOVAVAX INC (NVAX) Stock Chart to make your own analysis
- NOVAVAX INC (NVAX) Latest news and press-releases to stay up to date.
Does NOVAVAX INC (NVAX) stock pay dividends?
NVAX does not pay a dividend.
When does NOVAVAX INC (NVAX) report earnings?
NOVAVAX INC (NVAX) will report earnings on 2025-05-07.
What is the Price/Earnings (PE) ratio of NOVAVAX INC (NVAX)?
NOVAVAX INC (NVAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.65).
What is the Short Interest ratio of NOVAVAX INC (NVAX) stock?
The outstanding short interest for NOVAVAX INC (NVAX) is 26.75% of its float. Check the ownership tab for more information on the NVAX short interest.
NVAX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NVAX. When comparing the yearly performance of all stocks, NVAX is one of the better performing stocks in the market, outperforming 85.24% of all stocks.
NVAX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVAX. NVAX may be in some trouble as it scores bad on both profitability and health.
NVAX Financial Highlights
Over the last trailing twelve months NVAX reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 70.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.02% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NVAX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to NVAX. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 147.91% and a revenue growth -1.31% for NVAX